Allt inom Q2
Nanexa publishes interim report for April – June 2026
Strong commitment and a focus on the commercial side of the business.
Nanexa publishes interim report for January-June 2025
The second quarter of 2025 has continued to validate our core belief at Nanexa that slow-release medicines can transform how we dose and therefore treat people living with a range of conditions. Reducing the frequency of injections will improve compliance, treatment outcomes, and quality of life for patients.